B2B marketing in the sciences is definitely different to generic marketing. Not only are scientific discoveries and biotechnology developments complex, but they are also often taking a long time, have high stakes, and require trust by customers and/or end-users. Thus, if you want to market to scientists, engineers, clinicians, or technically literate decision-makers, traditional B2B marketing playbooks will fail you.

Over the past decade, China has transformed its pharmaceutical sector, evolving from a generics-dominated market into a global engine for innovative drug development. This shift has been driven by a combination of regulatory reforms, substantial increases in research and development (R&D) investment, and the rapid expansion of clinical research and manufacturing capabilities. This article explores the key drivers behind China’s rise in innovative drug development.

The cell and gene therapy landscape is evolving. Directly editing the genome or subcellular processes isn’t an aspirational dream anymore, but a potentially game-changing class of therapeutics for life-threatening and seriously debilitating diseases. Zeeks was fortunate enough to attend ELRIG’s Cell and Gene Therapy conference in Cambridge, hearing from the scientists developing cell and gene therapies about innovations in development across a plethora of diseases and therape